Market Overview

UPDATE: Morgan Stanley Upgrades Vertex Pharmaceuticals to Equal-Weight; Interim CF Data


Morgan Stanley raises its rating on Vertex Pharmaceuticals (NASDAQ: VRTX) from Underweight to Equal-weight and raises its price target from $28 to 51.

Morgan Stanley says, "We upgrade VRTX to EW. CF data were better than anticipated, but key data unknowns still exist. We add VX-809 sales to our base case model."

VRTX closed at $58.12 on Monday.

Posted-In: Morgan StanleyAnalyst Color Upgrades Price Target Pre-Market Outlook Analyst Ratings


Related Articles (VRTX)

View Comments and Join the Discussion!

Partner Center